Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ketones

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Ketones. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-001341-27 Sponsor Protocol Number: Empire-2017 Start Date*: 2017-05-29
    Sponsor Name:Morten Schou
    Full Title: Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF)
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002614-12 Sponsor Protocol Number: ESR-17-13447(DAPA-HF) Start Date*: 2019-02-08
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Short-term Effects of Dapagliflozin on Peak VO2 in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes
    Medical condition: Stable symptomatic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001132-19 Sponsor Protocol Number: 1-10-72-67-17 Start Date*: 2017-07-04
    Sponsor Name:Aarhus University Hospital
    Full Title: Effects of Metformin on portal hypertension in patients with cirrhosis.
    Medical condition: cirrhosis and portal hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10036201 Portal hypertensions HLT
    20.0 100000004871 10009211 Cirrhosis liver LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003172-13 Sponsor Protocol Number: MERCURI Start Date*: 2021-10-14
    Sponsor Name:Amsterdam UMC
    Full Title: The renal and metabolic outcomes after sodium-glucose cotransporter 2 inhibitor in cardiac surgery – an open-label phase IV randomized controlled trial
    Medical condition: Cardiac surgery-associated acute kidney injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10080266 Stage 1 acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001072-29 Sponsor Protocol Number: BIA-2093-211/EXT Start Date*: 2017-06-29
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET S...
    Medical condition: refractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 years
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10065336 Partial epilepsy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) IT (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-021860-13 Sponsor Protocol Number: BIA-91067-301 Start Date*: 2010-11-11
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMIS...
    Medical condition: Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) AT (Completed) LV (Completed) DE (Completed) ES (Completed) PT (Completed) CZ (Completed) SK (Completed) BG (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002847-32 Sponsor Protocol Number: X358602 Start Date*: 2015-11-02
    Sponsor Name:XOMA (US) LLC
    Full Title: A Single-Dose Open-Label Study of XOMA 358 in Subjects with Congenital Hyperinsulinism (HI)
    Medical condition: Hypoglycaemia associated with congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020644 Hyperinsulinism NOS LLT
    19.0 100000004861 10022484 Insulin hypoglycaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003857-78 Sponsor Protocol Number: D-CN-52014-244 Start Date*: 2023-06-29
    Sponsor Name:Ipsen Pharma
    Full Title: A phase III, open-label, multicentre, single arm study to assess the efficacy and safety of the triptorelin 6-month formulation in Chinese paediatric participants with central precocious puberty
    Medical condition: Central Precocious Puberty
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002400-20 Sponsor Protocol Number: 81866 Start Date*: 2023-02-28
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Feasibility of empagliflozin as treatment for idiopathic pulmonary arterial hypertension
    Medical condition: Idiopathic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002379-40 Sponsor Protocol Number: CAFQ056B2278 Start Date*: 2012-01-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome
    Medical condition: Fragile X syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003566-41 Sponsor Protocol Number: NN5401-3816 Start Date*: 2013-09-11
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial investigating the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals versus insulin detemir once or twice daily plus meal time ins...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) SI (Completed) ES (Completed) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001091-11 Sponsor Protocol Number: BIA-2093-211 Start Date*: 2017-06-29
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET S...
    Medical condition: refractory epilepsy with partial-onset seizures in children aged from 1 month to < 2 years
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10065336 Partial epilepsy LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) IT (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-003148-39 Sponsor Protocol Number: NN1250-3561 Start Date*: 2011-11-30
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in children and adolescents 1 to less than 18 yea...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) BG (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002763-25 Sponsor Protocol Number: NT2013/Orv/Prot001 Start Date*: 2013-10-11
    Sponsor Name:NeRRe Therapeutics Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in on...
    Medical condition: Intense pruritus, in oncology subjects, induced by EGFRi
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10023084 Itching LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005778-11 Sponsor Protocol Number: NP031112-08B03 Start Date*: 2009-01-29
    Sponsor Name:Noscira S.A.
    Full Title: A 14 week double-blind, placebo-controlled, randomized, escalating dose study to evaluate the safety and tolerability of three oral doses of NP031112, a novel GSK3 inhibitor, in mild to moderate Al...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023198-21 Sponsor Protocol Number: STH15295 Start Date*: 2011-05-25
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: The Relative Effectiveness of Pumps Over MDI and Structured Education.
    Medical condition: Type-1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004120-11 Sponsor Protocol Number: GN17DI706 Start Date*: 2020-05-05
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-001398-30 Sponsor Protocol Number: MEDOPP437 Start Date*: 2023-05-08
    Sponsor Name:Medica Scientia Innovation Research, S.L.
    Full Title: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 M...
    Medical condition: Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006752-14 Sponsor Protocol Number: DualActionWeightLossinIIH1 Start Date*: 2022-08-23
    Sponsor Name:Rigshospitalet, Neurologisk afdeling
    Full Title: Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension
    Medical condition: Idiopathic Intracranial Hypertension (IIH) is a disease in which the intracranial pressure is pathologically elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction....
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10004277 Benign intracranial hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001922-14 Sponsor Protocol Number: 1245.69 Start Date*: 2015-05-27
    Sponsor Name:Boehringer Ingelheim Ltd
    Full Title: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 5...
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) SE (Completed) FI (Completed) DK (Completed) DE (Completed) NL (Completed) CZ (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:17:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA